The Cystic Fibrosis Center at CWRU conducts translational research, with preclinical and clinical research projects that utilize a number of coe facilities. This application requests funds for 5 biomedical research cores, an administrative component and 2 pilot and feasibility projects. The cores include an internationally utilized 1. Mouse Models Core that provides mice and relevant assays for in vivo studies;2) a Bioanalyte Core to measure a range of molecules routinely analyzed by investigators;3) a Clinical Studies Core to facilitate clinical research projects;4) a Biostatistics and Bioinformatics Core to accommodate the evolving and increasing statistical and computations needs of Center investigators, and 5) a Rodent Imaging Core to provide in vivo monitoring for various studies. The purpose of these cores, administrative and feasibility components are:1) to provide researchers with state of the art core facilities and necessary reagents to optimize and improve the throughput of their CF-related research while maintaining or improving the quality of studies by providing centralized services. This goal is realized by the Biomedical Research Cores. 2) to provide a centralized resource for coordinating activities of the CF Center, including allocation o pilot and feasibility awards, an enrichment program and interaction with other institutional resources (other cores, CTSA, etc.). This goal will be addressed by the Administrative Component and executive committee. 3) to bring research discoveries to the clinic. Our CF Center has a long track record implementing this goal and proposes to continue to do so, capitalizing on new and exciting developments from within our Center as well as through collaborations with outside investigators. This goal is facilitated by the Biomedical Research Cores, with specific emphasis on the Clinical Studies Core. 4) to provide training and mentoring in CF-related research for students and fellows embarking on research projects, as well as investigators pursuing new avenues of research. This goal is also a function of the Biomedical Research Cores.

Public Health Relevance

Core facilities and infrastructural support have expedited CF research and reduced costs while accelerating the processes of moving science to therapy. The cores described in this application are all relevant to improving our understanding of cystic fibrosis and using that information to develop and improve therapies.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (J1))
Program Officer
Mckeon, Catherine T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Schools of Medicine
United States
Zip Code
Lai, Nicola; M Kummitha, China; Rosca, Mariana G et al. (2018) Isolation of mitochondrial subpopulations from skeletal muscle: Optimizing recovery and preserving integrity. Acta Physiol (Oxf) :e13182
Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2017) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros 16:283-290
Darrah, Rebecca; Nelson, Rebecca; Damato, Elizabeth G et al. (2016) Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function. Biol Res Nurs 18:498-504
VanDevanter, Donald R; Morris, Nathan J; Konstan, Michael W (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:372-9
VanDevanter, D R; Flume, P A; Morris, N et al. (2016) Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:783-790
Jiang, Kai; Jiao, Sen; Vitko, Megan et al. (2016) The impact of Cystic Fibrosis Transmembrane Regulator Disruption on cardiac function and stress response. J Cyst Fibros 15:34-42
Bruscia, Emanuela M; Bonfield, Tracey L (2016) Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun 8:550-563
Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21
Rymut, Sharon M; Kampman, Claire M; Corey, Deborah A et al. (2016) Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 311:L317-27
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87

Showing the most recent 10 out of 445 publications